Compass Pathways Q1 2026: Cash Runway Into 2027, Awaiting Pivotal Data

What happened

Compass Pathways reported Q1 2026 financial results, highlighting $185.9M in cash that funds operations into 2027, with net loss of $137.7M in Q3 2025 (including non-cash warrant revaluation). The company reiterated positive COMP005 Phase 3 top-line data and full enrollment of COMP006, with combined 26-week (COMP005) and 9-week (COMP006 Part A) readouts expected in Q1 2026. Management noted a positive FDA Type B meeting and potential for rolling NDA submission, but cautioned that additional capital will be needed for commercialization. Pre-commercial efforts continue via CPT III codes and collaborations with Hackensack Meridian and Radial, though Schedule I status and uncertain reimbursement remain structural overhangs. At $6.71, the stock embeds substantial success probability for COMP360, making risk-reward unattractive until data de-risk the approval path.

Implication

Investors should remain on the sidelines until combined COMP005 26-week and COMP006 Part A data in Q1 2026 clarify durability and safety. If data show robust efficacy without new safety signals, the probability of FDA acceptance rises, potentially supporting a re-rating toward the $9 base case. Conversely, weak durability or safety issues could send the stock below $4, as reflected in the 35% bear case. The cash runway into 2027 reduces near-term dilution risk, but the need for substantial future capital raises caps upside in the absence of strong data. Given the current price near the report's attractive entry of $5.50, patience is warranted—wait for the next catalyst.

Thesis delta

The Q1 2026 update reinforces the existing WAIT thesis; no fundamental shift has occurred. The key binary catalysts remain on track for Q1 and early Q3 2026, with commercial preparations advancing but still dependent on regulatory and rescheduling milestones. The risk-reward remains asymmetric to the downside at current levels, supporting the view to wait for a pullback or data de-risking.